Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Chia-Jen Liu, MD PhD, Raymond P. Perez, MD, Paul Richardson, Kenneth C. Anderson, MD, Jacob Laubach, MD, Patrick Henrick, BS, Alexandra Savell, BS, Kaitlen Reyes, NP, Kalvis Hornburg, BA, Stacey Chuma, BSN, Peter Sabbatini, Pamela S. Becker, MD

Blood (2018) 132 (Supplement 1): 3263.

https://doi.org/10.1182/blood-2018-99-117773

Published: 2018

Journal Articles

Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Blood (2015) 126 (23): 4256.

https://doi.org/10.1182/blood.V126.23.4256.4256

Published: 2015

Journal Articles

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Jacob P. Laubach, MD, Kenneth H. Shain, MD PhD, Rachid Baz, MD, Erica N Boswell, BS, Patrick M Henrick, MPH, Abdel Kareem Azab, Bpharm, PhD, Courtney Hanlon, Stacey Chuma, BSN, Houry Leblebjian, PharmD, BCOP, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Diane Warren, Philippe Armand, MD PhD, Claudia E. Paba-Prada, MD, Nikhil C. Munshi, MD, Robert L Schlossman, MD, Kenneth C. Anderson, MD, Paul G. Richardson

Blood (2014) 124 (21): 5777.

https://doi.org/10.1182/blood.V124.21.5777.5777

Published: 2014

Journal Articles

A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2014) 124 (21): 2142.

https://doi.org/10.1182/blood.V124.21.2142.2142

Published: 2014

Journal Articles

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, MD, Robert Allyn Redd, MS, Jeffrey Matous, Philippe Armand, MD PhD, Erica N Boswell, BS, Stacey Chuma, BSN, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, PharmD, BCOP, Diane Warren, Jorge J. Castillo, MD, Jacob P. Laubach, MD, Claudia E. Paba-Prada, MD, Kenneth C. Anderson, MD, Paul G. Richardson, Edie A. Weller, PhD, Steven P Treon, MD MA, PhD

Blood (2014) 124 (21): 3081.

https://doi.org/10.1182/blood.V124.21.3081.3081

Published: 2014

Journal Articles

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Kenneth Shain, MD, PhD, Courtney Hanlon, Ranjit Banwait, Abdel Kareem Azab, Bpharm, PhD, Jacob P. Laubach, MD, Philippe Armand, MD, PhD, Nikhil C. Munshi, MD, Robert L Schlossman, MD, Stacey Chuma, BSN, Erica N Boswell, BS, Patrick Mostyn, Leblebjian Houry, PharmD, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2013) 122 (21): 1947.

https://doi.org/10.1182/blood.V122.21.1947.1947

Published: 2013

Journal Articles

Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Jacob P. Laubach, MD, Noopur Raje, MD, Philippe Armand, MD, PhD, Robert L. Schlossman, MD, Erica N Boswell, BS, Courtney Hanlon, Stacey Chuma, BSN, Damian R Handisides, Stewart Kroll, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2013) 122 (21): 1948.

https://doi.org/10.1182/blood.V122.21.1948.1948

Published: 2013

Journal Articles

Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Irene M. Ghobrial, MD, Erica N Boswell, BS, Stacey Chuma, BSN, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, PharmD, BCOP, Diane Warren, Patrick Mostyn, Farzana Masood, Paul G. Richardson, MD, Steven Peter Treon, MD, MA, PhD, Jeffrey Matous, MD

Blood (2013) 122 (21): 4402.

https://doi.org/10.1182/blood.V122.21.4402.4402

Published: 2013

Journal Articles

Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, MD, Ranjit Banwait, MA, Tiffany Poon, BS, Federico Campigotto, MS, Erica N Boswell, BS, Stacey Chuma, BSN, Janet Kunsman, NP, Amanda Donovan, BS, Meghan Bagshaw, Diane Warren, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Edie Weller, PhD, Timothy J. Murphy, MD, FACP, Jeffrey Matous, MD

Blood (2011) 118 (21): 2706.

https://doi.org/10.1182/blood.V118.21.2706.2706

Published: 2011

Journal Articles

Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Irene M. Ghobrial, MD, Erica N Boswell, BS, Ranjit Banwait, MA, Tiffany Poon, BS, Amanda Donovan, BS, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Meghan Bagshaw, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Steven Treon, MD, PhD

Blood (2011) 118 (21): 2705.

https://doi.org/10.1182/blood.V118.21.2705.2705

Published: 2011

Journal Articles

Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Ranjit Banwait, MA, Abdel Kareem Azab, Bpharm, PhD, Phong Quang, BS, Jacob P. Laubach, MD, Amanda Donovan, BS, Meghan Bagshaw, Philippe Armand, MD, PhD, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Kenneth C. Anderson, MD, Paul G. Richardson, MD

Blood (2011) 118 (21): 1874.

https://doi.org/10.1182/blood.V118.21.1874.1874

Published: 2011

Journal Articles

Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma

Irene Ghobrial, MD, Abdel Kareem A. Azab, PhD, BSPharm, Jacob P. Laubach, MD, MPP, Ranjit Banwait, Meghan Rourke, Phong Quang, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Amy Sam, Eric Still, Brittany Morgan, Kenneth C. Anderson, Paul G Richardson

Blood (2010) 116 (21): 1943.

https://doi.org/10.1182/blood.V116.21.1943.1943

Published: 2010

Journal Articles

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Irene Ghobrial, MD, Tiffany Poon, BS, Meghan Rourke, Stacey Chuma, BSN, Janet Kunsman, NP, Ranjit Banwait, Amy Sam, Diane Warren, Kenneth C. Anderson, Paul Richardson, M.D., Ph.D., Steven P. Treon, MD, PhD, Jeffrey Matous, MD

Blood (2010) 116 (21): 3952.

https://doi.org/10.1182/blood.V116.21.3952.3952

Published: 2010

Journal Articles

Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib

Blood (2010) 116 (21): 990.

https://doi.org/10.1182/blood.V116.21.990.990

Published: 2010

NARROW

A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma

Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma

Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only